Clarity Pharmaceuticals was featured in ATSE Focus magazine, a publication issued by the Australian Academy of Technology and Engineering (ATSE), which publishes articles, reviews and letters to address national technology issues and key policy issues – such as innovation and productivity. The article highlights the benefits of using the Copper-64/Copper-67 pairing in the area of personalised medicine and discusses Clarity’s collaboration with Idaho State University’s Idaho Accelerator Centre regarding supply of therapeutic copper for clinical development.
Read the full article here:
http://biotechdispatch.com.au/clarity-establishes-european-subsidiary/#sthash.vlRgoIh5.VDwTViUT.dpbs
